GHRP-2 and estradiol jointly amplify pulsatile GH secretion versus GHRH in premenopausal women
Background
Pulsatile growth hormone secretion declines markedly with age and menopause in women, yet the independent contributions of age, estrogen status, and secretagogue type remain poorly disentangled. Physiological GH regulation depends on three main inputs: GH-releasing peptide (GHRP), GHRH, and somatostatin. Prior studies used pharmacological agonist doses that saturate receptors, masking relative potency differences between secretagogues. Abdominal visceral fat (AVF) and nonpulsatile basal GH secretion confound age-related comparisons, so controlling for these covariates is critical. Whether estradiol (E₂) specifically amplifies pulsatile versus nonpulsatile GH secretion — and whether this effect differs by menopausal status or by which peptide drives the pulse — had not been tested in a controlled experimental milieu.
Study Design
A prospectively randomized, double-blind, parallel-cohort study enrolled 20 premenopausal (PRE, age 24 ± 0.8 yr) and 22 postmenopausal (POST, age 63 ± 1.8 yr) healthy community-dwelling women. Gonadal-axis suppression was achieved with leuprolide, followed by randomized addback of transdermal E₂ or placebo. On separate days, subjects received iv bolus injections of a half-maximally stimulatory dose (0.33 µg/kg) of either GHRP-2 or GHRH. Primary analysis used three-way ANCOVA with main factors age, E₂ status, and secretagogue type, co-varying for AVF and basal (nonpulsatile) GH secretion.
Results
Submaximally stimulated pulsatile GH secretion was positively and independently determined by three factors: PRE vs. POST age (p < 0.001), E₂ repletion vs. depletion (p = 0.001), and GHRP-2 vs. GHRH stimulation (p < 0.001), all after covariate adjustment for AVF and basal GH secretion. E₂ versus placebo elevated fasting mean GH concentrations in both PRE and POST women (p = 0.006), but increased nonpulsatile basal GH secretion only in PRE women (p = 0.002), indicating an age-dependent mechanistic split. GHRH-driven GH secretory burst duration was prolonged by 36% in PRE versus POST women (p = 0.006), highlighting a structural difference in pulse kinetics beyond amplitude alone.
PRE vs. POST age, E₂ availability, and GHRP-2 vs. GHRH secretagogue type were triple independent determinants of pulsatile GH secretion — each significant at p ≤ 0.001 after controlling for visceral fat and basal GH output.
The convergence of all three factors in PRE women receiving E₂ and GHRP-2 represents the most stimulatory combination testable under this design, while POST women under E₂ depletion receiving GHRH represent the lowest-response condition.
Key Findings
- GHRP-2 vs. GHRH stimulation independently increased pulsatile GH secretion (p < 0.001) at matched submaximal doses
- Premenopausal vs. postmenopausal age positively determined pulsatile GH output (p < 0.001) independent of visceral fat
- Estradiol repletion vs. depletion elevated pulsatile GH secretion (p = 0.001) and fasting mean GH (p = 0.006) in both groups
- Estradiol increased nonpulsatile basal GH secretion only in premenopausal women (p = 0.002), not postmenopausal
- GHRH-driven GH secretory burst duration was 36% longer in premenopausal vs. postmenopausal women (p = 0.006)
Why It Matters
Clinicians and peptide users designing GH-stimulation protocols in women must account for menopausal status and concurrent estrogen exposure, not just dosing of the secretagogue itself. The finding that GHRP-2 outperforms GHRH at submaximal physiological doses suggests GHRP-class peptides retain an advantage independent of simple dose escalation — relevant for anyone seeking to avoid supraphysiological stimulation. The age-dependent split in how E₂ modulates basal versus pulsatile GH secretion implies that estrogen addback strategies may produce qualitatively different GH profiles in postmenopausal women versus premenopausal women, complicating one-size-fits-all HRT + secretagogue stacks. Translation to clinical protocols is feasible given that all interventions (leuprolide, transdermal E₂, iv GHRP-2, GHRH) are existing pharmacological tools, but the estrogen-clamp methodology used here is research-grade and not standard of care.
